Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma

BEKSAÇ, MERAL; Aydin, Yildiz; GÖKER, HAKAN; Turgut, Mehmet; Besisik, Sevgi; Cagirgan, Seckin; Tuglular, Tulin; VURAL, FİLİZ; Yagci, Munci; ALACACIOĞLU, İNCİ; Aytan, Pelin; Goksoy, Hasan; Gulbas, Zafer; Gunes, Ahmet; GÜRKAN, EMEL; Hacioglu, Sibel; Karti, Suleyman; KAYNAR, LEYLAGÜL; Ozdogu, Hakan; PAYDAŞ, SEMRA; Solmaz, Soner; SÖNMEZ, MEHMET; Tekgunduz, Emre; Yildirim, Rahsan; İLHAN, OSMAN

doi:10.1016/j.clml.2020.02.017

Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma

Atıf İçin Kopyala

BEKSAÇ M., Aydin Y., GÖKER H., Turgut M., Besisik S. K., Cagirgan S., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.20, sa.8, 2020 (SCI-Expanded)

Yayın Türü: Makale / Derleme
Cilt numarası: 20 Sayı: 8
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.clml.2020.02.017
Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Anahtar Kelimeler: EAP, Efficacy, RRMM, Safety, Survival, REFRACTORY MULTIPLE-MYELOMA, HISTORICAL CONTROL DATA, OPEN-LABEL, SURVIVAL, EFFICACY, CD38
Çukurova Üniversitesi Adresli: Evet

Özet

The present study investigated the efficacy and safety profile of daratumumab monotherapy in 42 patients with relapsed refractory multiple myeloma through a Turkish early access program. The current findings have confirmed the efficacy of daratumumab monotherapy in heavily pretreated patients with refractory multiple myeloma because of the deep and durable responses and favorable safety and tolerability profile.